好色先生

好色先生

Explore the latest content from across our publications

Log In

Forgot Password?
Create New Account

Loading... please wait

Abstract Details

Parkinson’s Disease Local Field Potential (LFP) Prevalence Tracking in GPi-DBS Via BrainsenseTM Survey
Movement Disorders
P4 - Poster Session 4 (8:00 AM-9:00 AM)
5-006

To characterize the local field potentials (LFPs) in Parkinson’s disease (PD) patients implanted in the globus pallidus internus (GPi) using the PerceptTM Deep Brain Stimulation (DBS) system. 

 

Innovation in the DBS space has led to a clinically available bidirectional system (PerceptTM) capable of stimulating and recording directly from the lead contacts. Clinical characterization of LFPs in chronically implanted PD patients have been primarily available for subthalamic (STN) DBS, there is less presented for GPi DBS.   

A quality assurance review of the BrainsenseTM survey at one institution was used for a longitudinal analysis in PD patients who underwent GPi-DBS.  Four survey time points (i.e. initial programming, 1, 3 and 6 months post-operatively) were included for analyses of LFP signals at the start of the programming session in the OFF-medicine state.  Baseline characteristics and clinical information was obtained from the baseline screening clinic. Indication for DBS placement varied amongst the subjects. All were implanted and managed at our institution.

Four PD patients, 2 males and 2 females, with a mean age of 73 were included for analysis. Average disease duration was 16 years. All 4 individuals had primary difficulties with dyskinesia, two were tremor dominant and two were akinetic-rigid subtype. The individuals selected were managed by our movement disorders neurologist. A beta peak signal [13-30Hz] signature could be identified on the BrainsenseTM survey in all four time points of variable power amongst the 4 patients. Additionally, alpha peak signals [8-12Hz] although present in all four participants demonstrated a higher power in the tremor dominant patients. No significant gamma peaks [31-200Hz] were captured.

GPi LFPs in the alpha and beta peak range correlating with symptoms were available and are stable for tracking over a 6-month period in patients implanted with the commercially available bidirectional system. 

Authors/Disclosures
Omolara Lawal, MD (University of Maryland Medical Center)
PRESENTER
Dr. Lawal has nothing to disclose.
Zahir Sheikh, MD (Penn State Milton S. Hershey Medical Center) Dr. Sheikh has nothing to disclose.
No disclosure on file
Marisa A. Kovach, PA (PennState Milton S Hershey Medical Center) Ms. Kovach has nothing to disclose.
No disclosure on file
Elana Farace, PhD Dr. Farace has nothing to disclose.
Sol T. De Jesus, MD (Penn State Milton S. Hershey Medical Center) Dr. De Jesus has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Medtronic Inc. Dr. De Jesus has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Medtronic Inc.